NASDAQ · Financial Statements

Structure Therapeutics Inc. (GPCR) Financial Statements

$53.36 NASDAQ: GPCR Market Cap $3.07B

Structure Therapeutics Inc. most recently reported annual revenue of $0, a net loss of $141.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Structure Therapeutics Inc.: net profit was positive in 0 of 6 reported years; the most recent year shows a net loss of $141.0M.

Income Statement — 6 Years (USD millions)

Metric202020212022202320242025
Revenue$0$0$0$0$0$0
Operating Expenses$16.0M$38.0M$53.0M$103.0M$158.0M$288.0M
Operating Profit$-16.0M$-38.0M$-53.0M$-103.0M$-158.0M$-288.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%0.0%
Other Income$0$0$1.0M$13.0M$36.0M$147.0M
Interest$0$0$0$13.0M$0$0
Depreciation$0$0$0$0$1.0M$4.0M
Profit Before Tax$-16.0M$-38.0M$-51.0M$-89.0M$-122.0M$-141.0M
Tax$-880,000$-610,000$-30,000$-260,000$-250,000$-370,000
Net Profit$-16.0M$-40.0M$-51.0M$-90.0M$-123.0M$-141.0M
EPS$-0.45$-1.20$-1.44$-2.43$-2.34$-2.40
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

6 duplicate period labels in the source data were collapsed.

MetricJun '23Sep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$26.0M$26.0M$31.0M$32.0M$33.0M$46.0M$47.0M$56.0M$70.0M$74.0M$-24.0M$90.0M
Operating Profit$-26.0M$-26.0M$-31.0M$-32.0M$-33.0M$-46.0M$-47.0M$-56.0M$-70.0M$-74.0M$24.0M$-90.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-23.0M$-23.0M$-25.0M$-26.0M$-26.0M$-34.0M$-36.0M$-47.0M$-62.0M$-66.0M$33.0M$-76.0M
Tax$-510,000$-1.7M$1.3M$-110,000$-200,000$-270,000$-370,000$-210,000$-230,000$-160,000$510,000$-250,000
Net Profit$-23.0M$-24.0M$-25.0M$-26.0M$-26.0M$-34.0M$-36.0M$-47.0M$-62.0M$-66.0M$33.0M$-76.0M
EPS$-0.60$-0.63$-0.54$-0.57$-0.54$-0.60$-0.63$-0.81$-1.08$-1.11$0.60$-1.05

Over the 6 years reported for Structure Therapeutics Inc., cash stood at $800.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 24.92 times.

Balance Sheet — 6 Years (USD millions)

Metric202020212022202320242025
Total Assets$39.0M$111.0M$98.0M$482.0M$903.0M$1.6B
Current Assets$38.0M$109.0M$93.0M$474.0M$891.0M$1.6B
Cash$16.0M$105.0M$26.0M$130.0M$170.0M$800.0M
Inventory$0$0$0$0$0$0
Receivables$0$0$0$0$0$0
Fixed Assets$0$2.0M$1.0M$8.0M$7.0M$13.0M
Capital Work in Progress$0$0$0$0$0$0
Investments$21.0M$2.0M$65.0M$338.0M$714.0M$647.0M
Other Assets$0$0$0$0$0$0
Total Liabilities$61.0M$176.0M$213.0M$29.0M$38.0M$68.0M
Current Liabilities$3.0M$9.0M$13.0M$25.0M$36.0M$63.0M
Borrowings$0$1.0M$0$5.0M$4.0M$6.0M
Other Liabilities$61.0M$175.0M$213.0M$24.0M$35.0M$61.0M
Equity$0$0$0$0$0$0
Reserves$-22.0M$-65.0M$-115.0M$453.0M$865.0M$1.5B

For Structure Therapeutics Inc., operating cash flow was positive in 0 of 6 reported years; free cash flow in the latest year was negative at $226.0M; free cash flow was positive in 0 of 6 years; financing activities used $5.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 6 Years (USD millions)

Metric202020212022202320242025
Operating Cash Flow$-14.0M$-32.0M$-46.0M$-79.0M$-117.0M$-222.0M
Investing Cash Flow$-21.0M$17.0M$-62.0M$-271.0M$-360.0M$86.0M
Financing Cash Flow$0$0$-2.0M$-21.0M$1.0M$-5.0M
Net Cash Flow$-10.0M$89.0M$-79.0M$104.0M$40.0M$630.0M
Free Cash Flow$-14.0M$-33.0M$-46.0M$-82.0M$-118.0M$-226.0M

Valuation & Return Ratios

MetricValue
PEG Ratio1.00
EV / EBITDA-16.46
FCF Yield-5.18%
Quick Ratio26.16
Interest Coverage—
Return 1Y176.86%
Return 3Y47.77%
Return 5Y—

Structure Therapeutics Inc. (GPCR) financials — frequently asked questions

What is Structure Therapeutics Inc.'s annual revenue?

Structure Therapeutics Inc. (GPCR) reported annual revenue of $0 in its most recent fiscal year.

What is Structure Therapeutics Inc.'s net profit?

Structure Therapeutics Inc. (GPCR) reported a net loss of $141.0M in its most recent fiscal year.

What is GPCR EV/EBITDA?

Structure Therapeutics Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -16.46. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
GPCR Overview GPCR Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.